In this Issue:
Afatinib active in advanced NSCLC harbouring uncommon EGFR mutations
EGFR TKIs: greater benefits in particular subgroups
Maintenance sunitinib improves PFS in extensive-stage SCLC
Nivolumab promising in previously treated advanced NSCLC
Necitumumab + chemotherapy: a first-line option for NSCLC?
Stereotactic ablative radiotherapy in operable stage I NSCLC
Surgery vs radiosurgery for stage I NSCLC
HSP90 inhibitor + erlotinib disappoints in EGFR mutant NSCLC
Carboplatin/paclitaxel + bevacizumab in Chinese patients with advanced NSCLC
Tobacco cessation improves lung cancer patient survival?
Please login below to download this issue (PDF)